406 related articles for article (PubMed ID: 21251579)
1. Cardiovascular mortality in chronic kidney disease patients undergoing percutaneous coronary intervention is mainly related to impaired P2Y12 inhibition by clopidogrel.
Morel O; El Ghannudi S; Jesel L; Radulescu B; Meyer N; Wiesel ML; Caillard S; Campia U; Moulin B; Gachet C; Ohlmann P
J Am Coll Cardiol; 2011 Jan; 57(4):399-408. PubMed ID: 21251579
[TBL] [Abstract][Full Text] [Related]
2. Impact of P2Y12 inhibition by clopidogrel on cardiovascular mortality in unselected patients treated by percutaneous coronary angioplasty: a prospective registry.
El Ghannudi S; Ohlmann P; Meyer N; Wiesel ML; Radulescu B; Chauvin M; Bareiss P; Gachet C; Morel O
JACC Cardiovasc Interv; 2010 Jun; 3(6):648-56. PubMed ID: 20630458
[TBL] [Abstract][Full Text] [Related]
3. Impaired inhibition of P2Y(12) by clopidogrel is a major determinant of cardiac death in diabetes mellitus patients treated by percutaneous coronary intervention.
El Ghannudi S; Ohlmann P; Jesel L; Radulescu B; El Adraa E; Crimizade U; Wiesel ML; Gachet C; Morel O
Atherosclerosis; 2011 Aug; 217(2):465-72. PubMed ID: 21524751
[TBL] [Abstract][Full Text] [Related]
4. Optimizing P2Y12 receptor inhibition in patients with acute coronary syndrome on the basis of platelet function testing: impact of prasugrel and high-dose clopidogrel.
Aradi D; Tornyos A; Pintér T; Vorobcsuk A; Kónyi A; Faluközy J; Veress G; Magyari B; Horváth IG; Komócsi A
J Am Coll Cardiol; 2014 Mar; 63(11):1061-70. PubMed ID: 24486281
[TBL] [Abstract][Full Text] [Related]
5. A randomized, double-blind, active-controlled phase 2 trial to evaluate a novel selective and reversible intravenous and oral P2Y12 inhibitor elinogrel versus clopidogrel in patients undergoing nonurgent percutaneous coronary intervention: the INNOVATE-PCI trial.
Welsh RC; Rao SV; Zeymer U; Thompson VP; Huber K; Kochman J; McClure MW; Gretler DD; Bhatt DL; Gibson CM; Angiolillo DJ; Gurbel PA; Berdan LG; Paynter G; Leonardi S; Madan M; French WJ; Harrington RA;
Circ Cardiovasc Interv; 2012 Jun; 5(3):336-46. PubMed ID: 22647518
[TBL] [Abstract][Full Text] [Related]
6. A randomized trial of prasugrel versus clopidogrel in patients with high platelet reactivity on clopidogrel after elective percutaneous coronary intervention with implantation of drug-eluting stents: results of the TRIGGER-PCI (Testing Platelet Reactivity In Patients Undergoing Elective Stent Placement on Clopidogrel to Guide Alternative Therapy With Prasugrel) study.
Trenk D; Stone GW; Gawaz M; Kastrati A; Angiolillo DJ; Müller U; Richardt G; Jakubowski JA; Neumann FJ
J Am Coll Cardiol; 2012 Jun; 59(24):2159-64. PubMed ID: 22520250
[TBL] [Abstract][Full Text] [Related]
7. Usefulness of platelet response to clopidogrel by point-of-care testing to predict bleeding outcomes in patients undergoing percutaneous coronary intervention (from the Antiplatelet Therapy for Reduction of Myocardial Damage During Angioplasty-Bleeding Study).
Patti G; Pasceri V; Vizzi V; Ricottini E; Di Sciascio G
Am J Cardiol; 2011 Apr; 107(7):995-1000. PubMed ID: 21256470
[TBL] [Abstract][Full Text] [Related]
8. Platelet reactivity in diabetic patients undergoing coronary stenting for acute coronary syndrome treated with clopidogrel loading dose followed by prasugrel maintenance therapy.
Cuisset T; Gaborit B; Dubois N; Quilici J; Loosveld M; Beguin S; Loundou AD; Moro PJ; Morange PE; Alessi MC; Dutour A; Bonnet JL
Int J Cardiol; 2013 Sep; 168(1):523-8. PubMed ID: 23084816
[TBL] [Abstract][Full Text] [Related]
9. Prognosis of patients suffering an acute coronary syndrome while already under chronic clopidogrel therapy.
Bonello L; De Labriolle A; Lemesle G; Steinberg DH; Roy P; Torguson R; Suddath WO; Satler LF; Kent KM; Pichard AD; Waksman R
Catheter Cardiovasc Interv; 2009 Jun; 73(7):866-70. PubMed ID: 19198009
[TBL] [Abstract][Full Text] [Related]
10. Long-term impact of mild chronic kidney disease in patients with acute coronary syndrome undergoing percutaneous coronary interventions.
Dohi T; Miyauchi K; Okazaki S; Yokoyama T; Tamura H; Kojima T; Yokoyama K; Kurata T; Daida H
Nephrol Dial Transplant; 2011 Sep; 26(9):2906-11. PubMed ID: 21300704
[TBL] [Abstract][Full Text] [Related]
11. Platelet reactivity after clopidogrel treatment assessed with point-of-care analysis and early drug-eluting stent thrombosis.
Sibbing D; Braun S; Morath T; Mehilli J; Vogt W; Schömig A; Kastrati A; von Beckerath N
J Am Coll Cardiol; 2009 Mar; 53(10):849-56. PubMed ID: 19264241
[TBL] [Abstract][Full Text] [Related]
12. The efficacy and safety of short- and long-term dual antiplatelet therapy in patients with mild or moderate chronic kidney disease: results from the Clopidogrel for the Reduction of Events During Observation (CREDO) trial.
Best PJ; Steinhubl SR; Berger PB; Dasgupta A; Brennan DM; Szczech LA; Califf RM; Topol EJ;
Am Heart J; 2008 Apr; 155(4):687-93. PubMed ID: 18371477
[TBL] [Abstract][Full Text] [Related]
13. Predictive values of post-treatment adenosine diphosphate-induced aggregation and vasodilator-stimulated phosphoprotein index for stent thrombosis after acute coronary syndrome in clopidogrel-treated patients.
Cuisset T; Frere C; Quilici J; Gaborit B; Castelli C; Poyet R; Bali L; Morange PE; Alessi MC; Bonnet JL
Am J Cardiol; 2009 Oct; 104(8):1078-82. PubMed ID: 19801028
[TBL] [Abstract][Full Text] [Related]
14. Impact of chronic kidney disease on platelet reactivity and outcomes of patients receiving clopidogrel and undergoing percutaneous coronary intervention.
Mangiacapra F; Cavallari I; Barbato E; Ricottini E; Patti G; Vizzi V; D'Ambrosio A; De Bruyne B; Wijns W; Di Sciascio G
Am J Cardiol; 2014 Apr; 113(7):1124-9. PubMed ID: 24507863
[TBL] [Abstract][Full Text] [Related]
15. High residual platelet reactivity after clopidogrel loading and long-term clinical outcome after drug-eluting stenting for unprotected left main coronary disease.
Migliorini A; Valenti R; Marcucci R; Parodi G; Giuliani G; Buonamici P; Cerisano G; Carrabba N; Gensini GF; Abbate R; Antoniucci D
Circulation; 2009 Dec; 120(22):2214-21. PubMed ID: 19917884
[TBL] [Abstract][Full Text] [Related]
16. Ticagrelor versus clopidogrel in patients with ST-elevation acute coronary syndromes intended for reperfusion with primary percutaneous coronary intervention: A Platelet Inhibition and Patient Outcomes (PLATO) trial subgroup analysis.
Steg PG; James S; Harrington RA; Ardissino D; Becker RC; Cannon CP; Emanuelsson H; Finkelstein A; Husted S; Katus H; Kilhamn J; Olofsson S; Storey RF; Weaver WD; Wallentin L;
Circulation; 2010 Nov; 122(21):2131-41. PubMed ID: 21060072
[TBL] [Abstract][Full Text] [Related]
17. Calcium-channel blockers reduce the antiplatelet effect of clopidogrel.
Siller-Matula JM; Lang I; Christ G; Jilma B
J Am Coll Cardiol; 2008 Nov; 52(19):1557-63. PubMed ID: 19007592
[TBL] [Abstract][Full Text] [Related]
18. Level of adenosine diphosphate receptor P2Y12 blockade during percutaneous coronary intervention predicts the extent of endothelial injury, assessed by circulating endothelial cell measurement.
Bonello L; Harhouri K; Sabatier F; Camoin-Jau L; Arnaud L; Baumstarck-Barrau K; Ait-Mokhtar O; Roubille F; Piot C; Lesavre N; Paganelli F; Dignat-George F
J Am Coll Cardiol; 2010 Sep; 56(13):1024-31. PubMed ID: 20846600
[TBL] [Abstract][Full Text] [Related]
19. GFR and cardiovascular outcomes after acute myocardial infarction: results from the Korea Acute Myocardial Infarction Registry.
Bae EH; Lim SY; Cho KH; Choi JS; Kim CS; Park JW; Ma SK; Jeong MH; Kim SW
Am J Kidney Dis; 2012 Jun; 59(6):795-802. PubMed ID: 22445708
[TBL] [Abstract][Full Text] [Related]
20. Clinical outcomes of high on-treatment platelet reactivity in Koreans receiving elective percutaneous coronary intervention (from results of the CROSS VERIFY study).
Park KW; Jeon KH; Kang SH; Oh IY; Cho HJ; Lee HY; Kang HJ; Park SK; Koo BK; Oh BH; Park YB; Kim HS
Am J Cardiol; 2011 Dec; 108(11):1556-63. PubMed ID: 21880289
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]